+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Clinical Trial Grant (CTG)

Cannonball Kids' Cancer Foundation

Cannonball Kids’ cancer (CKc) Foundation’s mission is to fund innovative, accessible research for children fighting cancer to provide better treatments and quality of life, and to educate for change. Our vision is to create cures for all childhood cancers.

About CKc

Cannonball Kids’ cancer Foundation was founded in 2014 by Michael and Melissa Wiggins, parents of Cannon Wiggins, who was diagnosed with Stage IV high-risk neuroblastoma when he was just 20 months old. During Cannon’s treatment, they learned that very little time, effort and funding is devoted to finding cures for children’s cancer compared to adult cancers, and as a result, children are unnecessarily and unjustly lost. CKc aims to stop the tragic reality of children suffering and dying because of the lack of research in the world of children’s cancer treatments. CKc believes "Research is the Key" that will unlock a cure, and the foundation has now awarded $5.4 million in research grants, providing an option for over 1,000 children who were told they had "no more options". Most of those studies are first-of-their-kind and are dispersed throughout 35 U.S. states, D.C., Puerto Rico, Canada, Scotland and Switzerland.

Grant Programs

CKc offers two types of research grants: Clinical Trial and Young Investigator. The maximum award amounts and durations for the 2026 cycle are as follows:

• Clinical Trial: $200,000 over 3 years

Funding Priorities

For the 2026 Grants Cycle, CKc will prioritize funding clinical trials and research that is nearing translation to a clinical trial. Grants funded by CKc must be innovative and provide better quality of life or symptom relief than current treatments.

For CKc, “innovation” means the invention or application of novel methods or treatments, specifically treatments that have fewer side-effects than standard care, increase a child’s quality of life, and/or create an option for care where there otherwise were few or none (either on primary diagnosis, relapse, or for recalcitrant cancers).

Whenever possible, CKc will prioritize funding research with a focus on:

• cancers that are under-funded or under-researched.

• with a focus on patient populations who are traditionally underserved.

AI Based Application Success Predictor

🧒 1. Strong Pediatric Cancer Focus (Non-Negotiable)

Projects must directly address:
- Childhood cancers (especially high-risk or relapsed cases)
Priority given to:
- Underfunded or rare pediatric cancers
- Underserved patient populations

👉 Adult oncology or indirect pediatric relevance → low success probability

🚀 2. Highly Innovative, First-of-Its-Kind Research (Top Predictor)

CKc explicitly funds:
- “innovative, first-of-its-kind research”
Innovation includes:
- Novel therapies
- New mechanisms or technologies
- Unexplored treatment strategies

👉 ~94% of funded trials are first-of-their-kind

💊 3. Clear Path to Clinical Trials (Critical Differentiator)

Strong preference for:
- Early-phase clinical trials
- Research close to trial readiness
Funding programs include:
- Clinical Trial Grants (~$200K)
- Translational projects nearing human studies

👉 Pure basic science without clinical trajectory is less competitive

🎯 4. Focus on Better Treatments (Less Toxic, More Effective)

Successful proposals demonstrate:

Therapies that:
- Reduce toxicity and side effects
- Improve survival and outcomes
- Enhance quality of life

👉 “Better than standard of care” is a key requirement

⚡ 5. Addressing Unmet Clinical Needs

Priority for:
- Relapsed/refractory cancers
- Conditions with limited treatment options
Focus on:
- Expanding treatment choices for children

👉 High unmet need = higher success probability

🔄 6. Translational & Impact-Oriented Research

Must show:
- Clear bench → bedside pathway
Emphasis on:
- Rapid movement toward patient benefit

👉 CKc is strongly impact-driven, not publication-driven

👩‍🔬 7. Investigator Capability & Clinical Environment

Requirements include:
- Affiliation with clinical departments
- Access to infrastructure and patient populations
PI must demonstrate:
- Ability to execute clinical or translational studies

🤝 8. Collaboration & Multidisciplinary Approach

Successful projects often involve:
- Oncology + immunology + translational science
Partnerships:
- Hospitals, clinical centers, research institutions

👉 Collaboration improves feasibility and scalability

🌍 9. Equity & Inclusion Considerations

CKc prioritizes:

Research involving:
- Underserved populations
- Diverse investigators

👉 Equity focus is a growing differentiator

🧪 10. Feasible, Milestone-Driven Study Design

Clear:
- Timeline
- Deliverables
Realistic within funding limits (often 1–3 years)

👉 Overly ambitious proposals are commonly rejected

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Pediatric cancer focus
First-of-its-kind innovation
Clear path to clinical trials

Moderate predictors:
4. Better/less toxic treatments
5. Addressing unmet needs
6. Translational relevance

Supporting factors:
7. Investigator capability
8. Collaboration
9. Equity considerations

💡 Insider Insight

Compared to other pediatric cancer funders:

Cannonball Kids' cancer Foundation is:
👉 extremely innovation + clinical-trial focused

👉 Key evaluation question:
“Will this create a new treatment option for children—and can it reach patients quickly?”

First-in-human or near-trial research ✔️
High-risk, high-reward ideas ✔️
Clear patient benefit ✔️
→ Highest success probability

Specialties

Cancer

Pediatrics

Oncology

Eligibility Requirements

• Applicants are limited to one Letter of Intent (LOI) per Principal Investigator (PI)

• PI must be employed by an academic or non-profit research institution or laboratory

• PI must be affiliated with a clinical department that supports the proposed research

• PI must have a medical doctoral degree: MD, DO, MD/PhD, or equivalent

• PI must demonstrate the potential to successfully conduct and complete the proposed clinical study and/or research

• The institution must have the infrastructure and resources necessary to support the proposed clinical study and/or research

Sponsor Details

Sponsor Institute/Organizations: Cannonball Kids' Cancer Foundation

Sponsor Type: Corporate/Non-Profit

Address: 1555 Howell Branch Rd., Suite C202 Winter Park

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity